BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 1310219)

  • 1. Central mineralocorticoid receptor antagonism blocks hypertension in Dahl S/JR rats.
    Gomez-Sanchez EP; Fort C; Thwaites D
    Am J Physiol; 1992 Jan; 262(1 Pt 1):E96-9. PubMed ID: 1310219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of 3beta-hydroxysteroid dehydrogenase inhibition by trilostane on blood pressure in the Dahl salt-sensitive rat.
    Gomez-Sanchez EP; Samuel J; Vergara G; Ahmad N
    Am J Physiol Regul Integr Comp Physiol; 2005 Feb; 288(2):R389-93. PubMed ID: 15458970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What is the role of the central nervous system in mineralocorticoid hypertension?
    Gómez Sánchez EP
    Am J Hypertens; 1991 Apr; 4(4 Pt 1):374-81. PubMed ID: 1647798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of brain mineralocorticoid receptor blockade on blood pressure and renal functions in DOCA-salt hypertension.
    Rahmouni K; Sibug RM; De Kloet ER; Barthelmebs M; Grima M; Imbs JL; De Jong W
    Eur J Pharmacol; 2002 Feb; 436(3):207-16. PubMed ID: 11858800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of central nervous system aldosterone synthase and mineralocorticoid receptors in salt-induced hypertension in Dahl salt-sensitive rats.
    Huang BS; White RA; Jeng AY; Leenen FH
    Am J Physiol Regul Integr Comp Physiol; 2009 Apr; 296(4):R994-R1000. PubMed ID: 19118098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intracerebroventricular infusion of RU28318 blocks aldosterone-salt hypertension.
    Gómez-Sánchez EP; Fort CM; Gómez-Sánchez CE
    Am J Physiol; 1990 Mar; 258(3 Pt 1):E482-4. PubMed ID: 2316642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Involvement of brain mineralocorticoid receptor in salt-enhanced hypertension in spontaneously hypertensive rats.
    Rahmouni K; Barthelmebs M; Grima M; Imbs JL; De Jong W
    Hypertension; 2001 Oct; 38(4):902-6. PubMed ID: 11641306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brain mineralocorticoid receptor control of blood pressure and kidney function in normotensive rats.
    Rahmouni K; Barthelmebs M; Grima M; Imbs JL; Wybren De Jong
    Hypertension; 1999 May; 33(5):1201-6. PubMed ID: 10334812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Central effects of mineralocorticoid antagonist RU-28318 on blood pressure of DOCA-salt hypertensive rats.
    Van den Berg DT; de Kloet ER; de Jong W
    Am J Physiol; 1994 Dec; 267(6 Pt 1):E927-33. PubMed ID: 7810636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of central infusion of benzamil on Dahl S rat hypertension.
    Gomez-Sanchez EP; Gomez-Sanchez CE
    Am J Physiol; 1995 Sep; 269(3 Pt 2):H1044-7. PubMed ID: 7573500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. On the role of brain mineralocorticoid (type I) and glucocorticoid (type II) receptors in neuroendocrine regulation.
    Ratka A; Sutanto W; Bloemers M; de Kloet ER
    Neuroendocrinology; 1989 Aug; 50(2):117-23. PubMed ID: 2550833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of mineralocorticoid action in the brain in salt-sensitive hypertension.
    Oki K; Gomez-Sanchez EP; Gomez-Sanchez CE
    Clin Exp Pharmacol Physiol; 2012 Jan; 39(1):90-5. PubMed ID: 21585422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of central amiloride infusion on mineralocorticoid hypertension.
    Gomez-Sanchez EP; Gomez-Sanchez CE
    Am J Physiol; 1994 Nov; 267(5 Pt 1):E754-8. PubMed ID: 7977727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The "mineralocorticoid-like" actions conferred on corticosterone by carbenoxolone are inhibited by the mineralocorticoid receptor (type I) antagonist RU28318.
    Souness GW; Morris DJ
    Endocrinology; 1991 Nov; 129(5):2451-6. PubMed ID: 1657575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Brain mineralocorticoid receptor and blood pressure control in the conscious normotensive rat].
    Rahmouni K; Barthelmebs M; Imbs JL; De Jong W
    Arch Mal Coeur Vaiss; 1998 Aug; 91(8):1009-12. PubMed ID: 9749155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of central mineralocorticoid binding sites in development of hypertension.
    Janiak PC; Lewis SJ; Brody MJ
    Am J Physiol; 1990 Nov; 259(5 Pt 2):R1025-34. PubMed ID: 2240262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mineralocorticoid receptor activation contributes to salt-induced hypertension and renal injury in prepubertal Dahl salt-sensitive rats.
    Kawarazaki H; Ando K; Nagae A; Fujita M; Matsui H; Fujita T
    Nephrol Dial Transplant; 2010 Sep; 25(9):2879-89. PubMed ID: 20466668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sex-specific effects of spironolactone on blood pressure in gonadectomized male and female Wistar rats.
    Michaelis M; Hofmann PJ; Götz F; Bartel C; Kienitz T; Quinkler M
    Horm Metab Res; 2012 Apr; 44(4):291-5. PubMed ID: 22266825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mineralocorticoids, salt and high blood pressure.
    Gómez-Sánchez EP; Zhou M; Gomez-Sanchez CE
    Steroids; 1996 Apr; 61(4):184-8. PubMed ID: 8732997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of sodium intake on the cardiovascular and renal effects of brain mineralocorticoid receptor blockade in normotensive rats.
    Rahmouni K; Barthelmebs M; Grima M; Imbs JL; De Jong W
    J Hypertens; 2002 Sep; 20(9):1829-34. PubMed ID: 12195126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.